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Liver glucose metabolism plays a central role in glucose homeostasis and may also regulate feeding and energy 
expenditure. Here we assessed the impact of glucose transporter 2 (Glut2) gene inactivation in adult mouse 
liver (LG2KO mice). Loss of Glut2 suppressed hepatic glucose uptake but not glucose output. In the fasted 
state, expression of carbohydrate-responsive element-binding protein (ChREBP) and its glycolytic and lipo-
genic target genes was abnormally elevated. Feeding, energy expenditure, and insulin sensitivity were identical 
in LG2KO and control mice. Glucose tolerance was initially normal after Glut2 inactivation, but LG2KO mice 
exhibited progressive impairment of glucose-stimulated insulin secretion even though β cell mass and insulin 
content remained normal. Liver transcript profiling revealed a coordinated downregulation of cholesterol 
biosynthesis genes in LG2KO mice that was associated with reduced hepatic cholesterol in fasted mice and 
reduced bile acids (BAs) in feces, with a similar trend in plasma. We showed that chronic BAs or farnesoid X 
receptor (FXR) agonist treatment of primary islets increases glucose-stimulated insulin secretion, an effect 
not seen in islets from Fxr–/– mice. Collectively, our data show that glucose sensing by the liver controls β cell 
glucose competence and suggest BAs as a potential mechanistic link.
Introduction
Hepatic glucose metabolism is highly regulated during the fed-to-
fast transition by changes in plasma levels of insulin and glucagon, 
but also by the changes in blood glucose concentrations. In the fed 
state, the presence of high insulin concentrations in the portal cir-
culation favors storage of glucose in the form of glycogen and the 
use of glucose through the glycolytic pathway for its conversion 
into fatty acids. Important regulatory events activated during the 
absorptive phase include the transcriptional induction of glucok-
inase by insulin and of L-pyruvate kinase by the carbohydrate-re-
sponsive element-binding protein (ChREBP), which translocates 
to the nucleus following its dephosphorylation by a glucose 
metabolite–activated phosphatase (1). At the same time, glucose 
inhibits glycogen phosphorylase through inhibition of glycogen 
phosphorylase phosphatase, whereas glucose-6-phosphate acti-
vates glycogen synthase (2), thus favoring glycogen biosynthesis. 
The combination of insulin-dependent Srebp-1c and glucose-de-
pendent ChREBP activation then induces the expression of lipo-
genic genes, including Acc, Fas, and Scd1 (1, 3).
In the fasted state, the decrease in glycemia reduces the 
intracellular levels of glucose and glucose-6-phosphate, thereby 
favoring glycogen degradation and reducing the activation of 
ChREBP and the expression of L-pyruvate kinase and lipogenic 
genes. Higher glucagon levels favor the gluconeogenic pathway 
by inducing the expression of PEPCK and G6Pase that catalyzes 
the hydrolysis of glucose-6-phosphate into glucose, a reaction that 
takes place in the lumen of the ER. The last steps of glucose output 
are classically described as involving glucose diffusion out of the 
ER into the cytosol followed by its export from the hepatocytes by 
facilitated diffusion through GLUT2. This view can be challenged 
on theoretical grounds since, as described above, cytosolic glucose 
suppresses glycogen phosphorylase activity, and its conversion 
into G6P activates glycogen synthase, thereby increasing glycogen 
accumulation. Glucose metabolism also induces L-type pyruvate 
kinase (L-PK) expression. These responses are all characteristic of 
the fed state. Therefore, glucose release from the ER lumen by a 
pathway that would compartmentalize glucose away from the cyto-
sol would provide a regulatory advantage. In previous studies (4, 5), 
we showed that the absence of GLUT2 suppressed glucose uptake 
and facilitated diffusion of glucose across the hepatocytic plasma 
membrane. However, in the fasted state, hepatic glucose output 
was normal, and we provided evidence that it was released through 
a membrane traffic–based mechanism. Some glucose could never-
theless still diffuse into the cytosol, but could not escape through 
GLUT2, leading to increased intracellular G6P levels, reduced gly-
cogen mobilization, and increased expression of L-PK (5). Thus, 
in the fasted state, GLUT2 was required to allow equilibration of 
cytosolic glucose with the extracellular glucose concentration to 
avoid the hepatocytes sensing a “fed” internal milieu. These conclu-
sions were, however, obtained by studying mice with a constitutive 
and systemic deletion of the Glut2 gene and activation of a compen-
satory, unphysiological pathway could not be excluded.
Besides regulating glucose homeostasis, hepatic glucose metab-
olism has also been proposed to control feeding and energy expen-
diture. Early studies suggested that intrahepatic ATP levels may 
participate in the control of feeding (6–10), possibly by utilizing 
the same vagus nerve pathways that link hypothalamic glucose 
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sensing to liver glucose metabolism (11). More recent work showed 
that overexpression of glucokinase or the bifunctional enzyme 
phosphofructo-2-kinase/fructose-2,6-bisphosphatase in the liver 
reduced feeding and body weight in obese mice. Increased activity 
of the bifunctional enzyme was also associated with reduced hypo-
thalamic neuropeptide Y (NPY) expression (12).
Here, we investigated the physiology of mice with liver-specific 
inactivation of the Glut2 gene induced in adult mice. Our data 
demonstrate that this suppressed glucose uptake by hepatocytes, 
but had no effect on hepatic glucose output and glucose homeo-
stasis in the fed or fasted states immediately after Glut2 gene inac-
tivation. However, glucose intolerance developed progressively 
because of altered β cell glucose competence without changes in 
islet insulin content and β cell mass. Microarray analysis of liver 
gene expression revealed that in addition to altered regulation 
of glycolytic and lipogenic gene expression, all of the cholesterol 
biosynthesis genes had reduced expression in both fasted and 
fed states. This was associated with reduced hepatic cholesterol 
concentrations and reduced bile acid (BA) production. Because 
BAs increase β cell glucose competence, we propose that their glu-
cose-dependent production may form the basis for a liver/pancre-
atic islet axis to control β cell glucose competence.
Results
Suppressed glucose uptake but normal glucose production after hepatic Glut2 
inactivation. To generate mice with liver-specific deletion of the Glut2 
gene, we first modified the Glut2 gene by homologous recombination 
in embryonic stem cells to flank exon 11 with LoxP sites. This exon 
encodes the last transmembrane domain and the cytoplasmic C-tail 
of the transporter and contains the 3′ untranslated region includ-
ing the polyadenylation site of the Glut2 gene (Figure 1A), a target-
ing strategy also used for conditional inactivation of the Glut4 gene 
(13). The presence of the Neo cassette did not interfere with GLUT2 
expression as revealed by Western blot analysis (Figure 1B). Deletion 
of the last transmembrane domain and C-tail of GLUT2 suppresses 
glucose transport activity (14, 15), as found for the deletion of the 
same transmembrane domain of GLUT8 (16) and GLUT4 (13).
To induce inactivation of the Glut2 gene in adult mouse livers, 
we crossed Glut2lox/lox mice with SA-CREERT2 mice (17) to generate 
Glut2lox/+;SA-CREERT2 mice, which were crossed together to obtain 
Glut2lox/lox;SA-CREERT2/SA-CREERT2 mice. Six-week-old mice were 
then injected with tamoxifen or oil on 3 consecutive days to 
induce Glut2 inactivation. As shown in Figure 1C, PCR analysis 
revealed the presence of the recombined Glut2 allele only in livers 
of tamoxifen-injected mice (LG2KO) but not in the kidney, brain, 
or duodenum of the same mice, nor in the liver of the oil-injected 
Glut2lox/lox;SA-CREERT2/SA-CREERT2 (control) mice. The presence of 
the remaining floxed allele in the liver is due to the presence of 
non-hepatocyte cells in this organ. Two days after the end of the 
tamoxifen treatment, GLUT2 expression was completely elimi-
nated in the liver of LG2KO mice, while its expression was nor-
mal in the kidney and islets (Figure 1D). Immunofluorescence 
and Western blot detection of GLUT2 in the liver of LG2KO mice 
showed no re-expression of the transporter 2 and 5 months after 
tamoxifen treatment (Figure 1E).
We previously reported that constitutive inactivation of the Glut2 
gene led to suppressed liver glucose uptake and facilitated diffu-
sion of glucose across the plasma membrane, but did not impair 
Figure 1
Liver-specific inactivation of the Glut2 
gene in adult mice. (A) Structure of the 
Glut2 floxed and CRE recombined alleles, 
and localization of the primers used for 
genotyping. (B) Western blot analysis of 
GLUT2 expression in the liver of mice with 
wild-type (WT) or floxed (G2 lox/lox) Glut2 
alleles. (C) PCR analysis revealed the 
presence of the recombined Glut2 allele 
in the liver of tamoxifen-treated Glut2lox/lox; 
SA-CREERT2 (LG2KO) mice; no recombi-
nation was found in the kidney, brain, or 
duodenum of these same mice, nor in the 
liver of oil-treated Glut2lox/lox;SA-CREERT2 
(Control) mice. (D) Western blot analysis 
of GLUT2 expression in liver, kidney, and 
pancreatic islets of control and LG2KO 
mice. (E) Immunofluorescence and West-
ern blot detection of GLUT2 in the liver of 
control and LG2KO mice 2 and 5 months 
after tamoxifen treatment. A vertical line 
separates nonadjacent lanes from the 
same blot. Scale bar: 50 μm.
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hepatic glucose production (4). Here, we showed by PET scanning 
of 18F-deoxy-D-glucose–injected (18FDG-injected) mice that glucose 
uptake was suppressed in the livers of LG2KO mice. This difference 
was not attributed to differences in the delivery of 18FDG to the 
liver from the systemic circulation (Figure 2C). However, hepatic 
glucose production in 6-hour–fasted mice, as measured by glucose 
clamp analysis, was identical between control and LG2KO mice 
(Figure 2D). Nevertheless, during the early fasting period blood 
glucose levels decreased more rapidly in the LG2KO mice than in 
control mice. This was caused by an impairment in hepatic glyco-
gen mobilization in the mutant mice (Figure 2, E and F) due to 
abnormal glucose and G6P intracellular levels which, respectively, 
reduce glycogen degradation and favor its synthesis (5).
Hepatic gene and protein expression analysis of fasted and fed 
mice revealed, first, that expression of the glucose-regulated tran-
scription factor ChREBP in the nuclear fraction of LG2KO mouse 
livers was similar to that found in the livers of fed control mice and 
was maintained at this high level in the fasted state (Figure 3A). 
In agreement with ChREBP deregulated expression, Lpk expres-
sion was increased in the liver of fasted compared with re-fed 
LG2KO mice (Figure 3B). The lipogenic genes Srebp-1c, Acca, Scd1, 
and Elovl6, which are also in part regulated by ChREBP, also had 
increased expression in fasted LG2KO mouse livers compared with 
the control mice. However, no significant differences were noted 
for Fas expression. The livers of LG2KO mice were also larger than 
those of the control mice (Figure 3C).
Thus, these data support our previous observations using mice 
with systemic and constitutive Glut2 gene inactivation. They show 
that hepatic glucose production can proceed normally in the 
absence of GLUT2 and glucose uptake capacity. They show that 
GLUT2 is nevertheless required for normal mobilization of glyco-
gen and for the suppression of glucose-regulated, ChREBP-depen-
dent gene expression in the fasted state.
Normal energy homeostasis in LG2KO mice. Because there have 
been reports that liver glucose metabolism, in particular hepatic 
glycogen metabolism, may impact feeding behavior and energy 
expenditure (6–10), we performed extensive evaluation of energy 
homeostasis in control and LG2KO mice. As shown in Figure 4A, 
body weight gain for up to 14 weeks after tamoxifen treatment 
was identical between control and mutant mice. Body composi-
tion assessed by echo MRI at the end of the experiment was the 
same, as were body temperature, food intake, heat production, 
physical activity, and respiratory quotient (Figure 4, B–G). Thus, 
the impairment in liver glucose and glycogen metabolism induced 
by Glut2 gene inactivation did not have an impact on body weight, 
feeding, or energy expenditure.
Figure 2
Absence of liver GLUT2 expression 
suppresses hepatic glucose uptake but 
does not impair endogenous glucose 
production. (A) PET imaging of 18FDG 
uptake by the liver and kidneys of con-
trol and LG2KO mice during the first 
15 minutes after injection (dorsal view; 
red, high uptake; green, low uptake). 
(B) Kinetics of 18FDG uptake by the 
liver of control (white squares, n = 6) 
and LG2KO (black circles, n = 8) mice. 
Note the suppression of 18FDG uptake 
between 1 minute and 9 minutes after 
injection in the liver of LG2KO mice. 
**P < 0.01 versus control mice. (C) 
Time-activity curve of 18FDG uptake in 
the blood of control (white squares, n = 6) 
and LG2KO (black circles, n = 8) mice 
acquired by imaging the inferior vena 
cava. Inset shows expanded view of the 
same graph from 0 to 3 minutes after 
tracer injection. (D) Endogenous glu-
cose production by control and LG2KO 
mice (n = 10). (E) Evolution of blood glu-
cose levels in fasted control and LG2KO 
mice (n = 9). ***P < 0.001 versus control 
mice. (F) Evolution of hepatic glycogen 
content in control and LG2KO mice in 
the indicated states (n = 5). **P < 0.01. 
Rd, rate of glucose disappearance; 
HGO, hepatic glucose output.
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Since liver mRNA analysis indicated increased lipogenic gene 
expression, we assessed hepatic triglyceride stores, de novo lipogene-
sis, and lipoprotein production. Triglyceride stores were lower in the 
fasted state in the livers of LG2KO mice compared with control mice 
as assessed by oil red O staining and biochemical measurements 
(Figure 5, A and B); de novo lipogenesis was decreased, although 
the reduction did not reach statistical significance (Figure 5C); 
and the rate of VLDL production was higher in the mutant mice 
with similar profiles of lipoprotein-associated triglycerides and 
cholesterol in the plasma of control and knockout mice (Figure 5, 
D and E). Thus, there was no steatosis, despite increased lipo-
genic gene expression and only a moderately increased rate of 
VLDL export. No indication of increased beta-oxidation could 
be observed as measured by plasma β-hydroxybutyrate levels (not 
shown). Thus, the apparently surprising absence of steatosis in 
LG2KO mouse livers is best explained by the absence of GLUT2, 
which prevents the provision of glucose as a lipogenic substrate.
Progressive development of glucose intolerance in LG2KO mice. To 
evaluate the impact of liver Glut2 gene inactivation on glucose 
homeostasis, we measured glycemia and insulinemia in the 
fasted, fed, and fasted/re-fed state in control and LG2KO mice. 
This was performed 4 weeks after tamoxifen treatment, and effi-
cient suppression of GLUT2 expression was verified by West-
ern blot analysis for each mouse studied. As shown in Figure 6, 
A–C, glycemic and insulinemic levels, as well as glucose toler-
ance, were identical in control and LG2KO mice. Glucose-stim-
ulated insulin secretion following i.p. glucose injection was also 
identical in control and LG2KO mice (Figure 6, D and E). This 
indicates that liver glucose uptake is not required for normal 
glucose homeostasis in the fed or fasted states, nor is it required 
for normal glucose tolerance.
To assess whether normal hepatic glucose uptake capacity is 
required for long-term maintenance of glucose homeostasis, we 
performed similar analysis 4 months after Glut2 inactivation. 
Figure 3
Abnormal regulation of glucose-sensitive genes in the livers of LG2KO mice. (A) Western blot analysis of ChREBP protein levels in nuclear frac-
tions from the livers of 24-hour–fasted mice (Fasted) and mice re-fed for 6 hours after the end of the 24 hours of fasting (Re-fed). Vertical lines 
separate nonadjacent lanes from the same blot (left). Quantification of ChREBP protein levels in nuclear fraction, and ChREBP mRNA levels in 
the liver of fasted and re-fed control and LG2KO mice (n = 6) (right). (B) Levels of expression of the indicated metabolic gene mRNA in the livers 
of fasted and re-fed control and LG2KO mice (n = 6). (C) Liver weight in fasted and re-fed control and LG2KO mice (n = 12). Data represent the 
mean ± SEM. *P < 0.05; **P < 0.01; and ***P < 0.001 versus control fasted mice. §§P < 0.01 and §§§P < 0.001 versus LG2KO fasted mice. #P < 0.05 
and ##P < 0.01 versus control re-fed mice.
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Although there were no differences in fed, fasted, and fasted/
re-fed glycemia and insulinemia, LG2KO mice developed glu-
cose intolerance (Figure 6, F–H). This was caused by a defect 
in insulin secretion, which was assessed following i.p. glucose 
injection (Figure 6, I and J), and was not related to a defect in 
plasma glucagon levels (Figure 6K), nor was it secondary to the 
development of insulin resistance as assessed by hyperinsuline-
mic-euglycemic clamp analysis in 5-hour–fasted mice (Figure 6L). 
However, reduced hepatic glucose output and rate of glucose 
disappearance were measured in basal clamp conditions, i.e., 
before insulin infusion (Figure 6, M and N), and were in line with 
the reduced mobilization of glycogen and lower glycemic levels 
observed early on during fasting in LG2KO mice (see Figure 2, 
D–F). In the presence of insulin, suppression of hepatic glucose 
output, as well as the rate of glucose disappearance, were not dif-
ferent between control and LG2KO mice (Figure 6, M and N). 
Measurements of 2-deoxy-glucose (2-DG) uptake during the 
hyperinsulinemic clamp revealed significantly increased uptake 
in the extensor digitorum longus (EDL) muscle. The uptake was 
higher but did not reach statistical significance in the tibialis 
anterior (TA) and gastrocnemius muscles, and there was no dif-
ference in uptake in the heart and perigonadal fat of control and 
LG2KO mice (Figure 6, O–Q). Thus, the absence of GLUT2 in the 
liver led to a redistribution of the infused glucose to peripheral 
tissues and to the development of glucose intolerance caused by 
reduced insulin secretion.
To further characterize the defect in insulin secretion, we per-
formed isolated islet perifusion and pancreas perfusion experi-
ments (Figure 7, A and B). Both experimental paradigms revealed 
a significant secretion defect that was present even though the 
insulin content per islet was identical in control and LG2KO islets, 
as were total pancreatic insulin content, β cell mass, and GLUT2 
expression (Figure 7, C–F). Together, these data show that the 
absence of GLUT2 in the liver induces progressive glucose intoler-
ance due to a defect in β cell glucose competence.
Hepatic glucose sensing controls a liver/β cell axis. Since the absence 
of GLUT2 from hepatocytes led to deregulated expression of 
glucose-sensitive glycolytic and lipogenic genes, we wondered 
whether other hepatic genes were also deregulated in fasted 
and fed conditions because of impaired glucose metabolism. 
We therefore performed microarray analysis of genes expressed 
in the liver of fasted and fed control and LG2KO mice and ana-
lyzed the expression data by gene set enrichment analysis (GSEA) 
(18). A single gene set that encodes the cholesterol biosynthesis 
enzymes behaved differently in both fasted and re-fed LG2KO 
mouse livers compared with control mouse livers (Figure 8A). 
Figure 8B shows the relative gene expression of the leading edge 
of the gene set in both fasted and re-fed states. These data show 
that in both states, there was a coordinated decreased expression 
of most of the genes of the cholesterol biosynthetic pathway in 
LG2KO mice. This was confirmed for a few genes by quantitative 
RT-PCR analysis (qRT-PCR) (Figure 8C). Identical results were 
obtained 2 weeks and 4 months after tamoxifen treatment. Also, 
to exclude the possibility that these changes in gene expression 
could be the result of the tamoxifen treatment rather than Glut2 
gene inactivation, we performed 2 control experiments. First, we 
verified that tamoxifen treatment did not affect the expression 
of cholesterol biosynthesis genes in Glut2lox/lox mice (not shown). 
Second, we analyzed the expression of some of these genes in 
the livers of mice with constitutive Glut2 gene inactivation 
(Ripglut1;Glut2–/– mice, KOG2) (19). The same reduction in these 
gene expressions was also present (Figure 8D).
Figure 4
Normal energy homeostasis in LG2KO mice. (A) Body weight. (B) Body composition measured by echo MRI. (C) Body temperature. (D) Food 
intake. (E) Heat production. (F) Physical activity. (G) RER. Data represent the mean ± SEM (n = 6–8).
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Biochemical measurements of cholesterol showed a 30% decrease 
in cholesterol in the liver of fasted LG2KO mice compared with 
control mice. In the re-fed state, possibly as a result of cholesterol 
absorption from food, no difference in hepatic cholesterol levels 
was observed. In plasma, cholesterol concentrations were identical 
in LG2KO and control mice in either fasted or re-fed conditions 
(Figure 5 and Figure 9, A and B). Because cholesterol can also be 
converted to BAs in the liver, we measured individual and total BAs 
in LG2KO and control mice feces collected over 24 hours. There was 
a significant reduction in daily BA production in the LG2KO mice 
(Figure 9C) that variously affected the different individual BA spe-
cies, with large reductions in deoxycholic acid, α-murocholic acid, 
hyodeoxycholic acid, and β-murocholic acid (Figure 9D). In plasma, 
there was an approximately 30% reduction in BAs in LG2KO mice 
that did not, however, reach statistical significance (Figure 9E). No 
change was observed in the expression of genes involved in BA pro-
duction (Cyp7A1, Cyp27A1, Cyp46A1, Cyp39A1, and Cyp8B1).
Previous reports have indicated that BAs may impact glucose 
homeostasis by a TGR5-dependent stimulation of GLP-1 secretion 
(20) and by direct BA action on β cells (21, 22). We thus measured 
GLP-1 levels in the portal vein of control and LG2KO mice 30 min-
utes after a re-feeding period, but could not detect any difference 
in GLP-1 secretion (11.6 ± 2.2 pM vs. 18.4 ± 5.2 pM; mean ± SEM, 
n = 12 and 14 for control and LG2KO mice, respectively). We then 
evaluated whether BAs could acutely increase glucose-stimulated 
insulin secretion. We could not detect any significant effect of 
lithocholic acid (a preferential TGR5, rather than FXR, agonist) or 
of a mixture of BAs (cholic acid, taurocholic acid, deoxycholic acid, 
taurochenodeoxycholic acid, each at 50 μM) on 20 mM glucose-
stimulated secretion, used at concentrations that are largely above 
their Kd for TGR5 or FXR (20, 23) (not shown).
We next tested whether BAs could control β cell glucose compe-
tence through treatment of islets with BAs or the GW4064 agonist 
of the BA receptor FXR, known to be expressed in islet cells (21). 
Islets were thus pre-exposed for 48 hours in the presence of CDCA 
(chenodeoxycholic acid) or GW4064. As shown in Figure 9F, pre-
incubation with the BA or the synthetic agonist led to an increased 
stimulation of insulin secretion. This effect was dependent on FXR 
activity, as demonstrated by the lack of stimulation when the exper-
iments were performed with islets from Fxr–/– mice (Figure 9G). 
Finally, we compared the effects of pre-exposure with TGR5, FXR, 
and GLP-1 receptor agonists on the secretion response. Primary 
Figure 5
Impaired lipid metabolism in 
LG2KO mice. (A) Oil red O 
staining of liver sections from 
fasted and re-fed control or 
LG2KO mice. Scale bar: 50 μm. 
(B) Quantification of TG stor-
age in the liver of control 
and LG2KO mice. **P < 0.01 
versus control fasted mice. (C) 
Fractional de novo lipogene-
sis measured over a 24-hour 
period. (D) VLDL secretion 
rates from overnight-fasted 
control and LG2KO mice. 
Secreted TG at the indicated 
time points after tyloxa-
pol injection for control and 
LG2KO mice (left); rate of TG 
secretion derived from the 
left graph (right). *P < 0.05; 
**P < 0.01; and ***P < 0.001 
versus control. (E) Triglycerides 
(left) and cholesterol (right) 
contents of FPLC-fractionated 
plasma from 24-hour–fasted 
control and LG2KO mice. Data 
represent the mean ± SEM 
(n = 6–8).
Downloaded on April  8, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/65538
research article
1668 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 4   April 2013
Figure 6
Progressive development of glucose intolerance in LG2KO mice. (A–C) Five days after the end of tamoxifen treatment, glycemia (A), insulinemia 
(B), and i.p. glucose tolerance (C) were identical in control and LG2KO mice (n = 12). (D) Glycemia and (E) insulinemia at the indicated time 
after an i.p. injection of glucose. (F–H) Four months after tamoxifen treatment, glycemia (F) and insulinemia (G) were not different in control and 
LG2KO mice (n = 12). (H) Glucose intolerance became evident following i.p. glucose injection (n = 12). (I) Glycemia and (J) insulinemia at the 
indicated time after an i.p. injection of glucose. (K) Glucagonemia (n = 6). For A, B, F, G, and K, fasting was for 24 hours and re-feeding was for 
6 hours after 24 hours of fasting. Fed mice were studied at the end of the dark period. (L) Insulin sensitivity assessed by the glucose infusion 
rate in hyperinsulinemic and euglycemic clamp experiments. (M) HGO before insulin infusion (Basal) and during the insulin clamp (Clamp). (N) 
Rate of glucose disappearance before (Basal) and during the insulin clamp (Clamp). 2-DG uptake in gastrocnemius (Gastroc.), TA, and EDL 
muscles (O) in heart (P) and in perigonadal fat (WAT) (Q) during the insulin clamp (n = 7). *P < 0.05; **P < 0.01; and ***P < 0.001 versus control.
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islets were treated for 48 hours with RG-239 (a TGR5 agonist), 
CDCA, or exendin-4, and the secretion experiments were per-
formed in the continuous presence of the indicated compounds. 
RG-239 did not have an impact on 20 mM GSIS, GW4064 induced 
approximately 4-fold increased secretion, and exendin-4 induced 
an approximately 21-fold increase in secretion (Figure 9H).
The above data show that the absence of GLUT2 in the liver 
induced a coordinated decrease in cholesterol biosynthesis genes, 
which led to a decrease in BA production with no discernible impact 
on plasma cholesterol levels. Our results demonstrating that BAs can 
increase the glucose competence of β cells through FXR-dependent 
mechanisms suggest that BAs could be effectors of a liver/β cell axis.
Discussion
Our present data show that direct glucose uptake by the liver 
is not critical for the control of glucose homeostasis in the fed 
and fasted states. However, the absence of GLUT2 impairs gly-
cogen mobilization during fasting and prevents normal regu-
lation of glycolytic and lipogenic gene expression. This is also 
associated with a coordinated downregulation of the choles-
terol biosynthesis genes leading to lower BA production. These 
deregulations of liver glucose metabolism do not modify feeding 
behavior or energy homeostasis. However, they lead to progres-
sive development of glucose intolerance due to a reduced insulin 
secretory capacity. Our data suggest that BAs may constitute a 
link between hepatic glucose sensing and the preservation of 
β cell glucose competence.
Suppression of GLUT2 expression in hepatocytes in systemic 
Glut2 knockout mice was previously demonstrated to suppress 
glucose uptake while retaining normal hepatic glucose produc-
tion. Here, using a mouse model with selective inactivation of 
Glut2 in the liver of adult mice, we confirm that glucose could 
no longer be taken up by hepatocytes, while hepatic glucose 
production remained unchanged in fasted mice. This confir-
mation of our previous data is important since it could have 
been argued that the suppression of Glut2 expression from birth 
Figure 7
Reduced insulin secretory capacity in islets from LG2KO mice. (A) Four months after tamoxifen treatment, islets were isolated from control and 
LG2KO mice and insulin secretion was tested in perifusion experiments using the indicated glucose concentrations. AUC of the insulin secretion 
activity is represented on the right (n = 7). For AUC: Student’s t test, *P < 0.05 versus control. (B) Pancreas perfusion experiments revealed a 
reduced secretory capacity of the endocrine pancreas of LG2KO mice (n = 4). A and B (insulin secretion graphs): 2-way ANOVA, *P < 0.05 ver-
sus control mice. (C) Insulin per islet DNA (n = 7). (D) Pancreatic insulin content (n = 6), and (E) β cell mass in control and LG2KO mice (n = 4). 
(F) Immunofluorescence detection of GLUT2 in control and LG2KO pancreatic islets. Scale bar: 30 μm.
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Figure 8
GSEA reveals a decreased expression of cholesterol biosynthesis genes in fasted and re-fed states. Fasting was for 24 hours and re-feeding 
was for 6 hours after 24 hours of fasting. (A) GSEA of microarray data from fasted and re-fed control and LG2KO mice reveal enrichment in cho-
lesterol biosynthesis genes in both conditions. (B) Heat map representing the level of expression of genes in the leading edge of the cholesterol 
biosynthesis gene set (official gene symbols are used). Expression level increases from blue to red. (C) qRT-PCR analysis of the expression of the 
indicated cholesterol biosynthesis genes in livers of fasted and re-fed control and LG2KO mice. **P < 0.01 versus control fasted mice. §P < 0.05 
and §§P < 0.01 versus LG2KO fasted  mice. #P < 0.05 and ##P < 0.01 versus control re-fed mice (n = 6). (D) Expression levels of the indicated 
cholesterol biosynthesis genes in livers of fasted and re-fed C57Bl/6 mice (B6) and mice with constitutive Glut2 knockout (Ripglut1;Glut2–/– mice 
backcrossed on a B6 background, KOG2). **P < 0.01 and ***P < 0.001 versus B6 fasted mice. §P < 0.05 versus KOG2 fasted mice. #P < 0.05 
versus B6 re-fed mice (n = 6).
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could lead to nonphysiological induction of an adaptive process 
to preserve glucose output capacity. Tamoxifen-induced Glut2 
inactivation is a rapid event, taking place over a few days, and no 
impairment in glycemic control was observed, even in glucose 
tolerance tests. This indicates that hepatic glucose uptake is not 
a major component of glucose disposal in the absorptive phase 
or that redirection of glucose fluxes to skeletal muscles may rap-
idly compensate for impaired liver glucose uptake. The fact that 
fasting was associated with normal hepatic glucose production 
supports our previous conclusions that the release of glucose 
from hepatocytes may take a pathway which does not depend on 
facilitated diffusion through the plasma membrane, but rather 
Figure 9
Reduced cholesterol and BA levels in LG2KO mice and potentiation of insulin secretion by BAs. (A) Liver cholesterol content and (B) plasma 
cholesterol in fasted and re-fed control and LG2KO mice (n = 6). (C) BA content in feces of control and LG2KO mice collected over a 24-hour 
period (n = 7). (D) Composition of the fecal BAs: α-murocholic acid (α-M); deoxycholic acid (DC); cholic acid (C); chenodeoxycholic acid (CDC); 
hyodeoxycholic acid (HDC); tauro-β-murocholic acid (Tβ-M); and β-murocholic acid (β-M) (n = 7). (E) Total plasma BAs in the fasted state (n = 6). 
A–E: *P < 0.05; **P < 0.01; and ***P < 0.001 versus control. (F) Twenty-four-hour pretreatment of control islets with chenodeoxycholic acid (CDCA, 
50 μM), or the FXR agonist GW4064 (1 μM) increases glucose-stimulated insulin secretion. DMSO: vehicle. (G) No potentiation of glucose-
stimulated insulin secretion by FXR agonists in Fxr–/– islets. (H) One-hour glucose-stimulated insulin secretion by control islets performed in the 
presence of, and after a 48-hour treatment with, TGR5 (RG-239), FXR (CDCA), or GLP-1 receptor (exendin-4 [Ex4]) agonists. F–H: Pool of 5 
different experiments. One-way ANOVA and post-hoc Tukey’s test: *P < 0.05; **P < 0.01; and ***P < 0.001. In H, statistical significance is calculated 
versus DMSO-treated islets.
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reduced insulin secretion by β cells, whose total mass and insulin 
content remained normal. This therefore suggests the existence 
of a liver/β cell axis that depends on normal liver glucose metab-
olism and correct regulation of gene expression by glucose. That 
hepatic glucose metabolism may influence β cell function was 
previously noted in a study of mice with liver-specific knock-
out of the glucokinase gene; in the basal state, mutated and 
control mice insulinemia was not different, but was reduced by 
approximately 70% in the knockout mice during hyperglycemic 
clamps (29). GSEA of genes expressed in control and LG2KO liv-
ers revealed that besides the deregulation of glycolytic and fatty 
acid synthesis genes, there was a coordinated downregulation of 
most of the cholesterol biosynthesis genes, both in fasted and 
re-fed states. Quantitative analysis showed lower expression of 
Srebp-2 in the re-fed, but not in the fasted, state in LG2KO mice 
compared with control mice, suggesting that posttranslational 
modifications, such as phosphorylation, acetylation, or O-gly-
cosylation (30, 31), may also contribute to a change in SREBP 
activity. Understanding the link between hepatic glucose sensing 
and control of cholesterol biosynthesis genes will clearly require 
further investigation.
The decrease in cholesterol biosynthesis gene expression was 
associated with a 30% reduction in hepatic cholesterol content. 
This was observed in the fasted but not the re-fed state, and 
plasma cholesterol levels were the same between LG2KO and 
control mice in all conditions, suggesting that some of this cho-
lesterol could come from absorbed food. Cholesterol is also the 
precursor for BA biosynthesis (32), and fecal BAs were reduced in 
LG2KO mice. No changes were observed in Cyp7A1 gene expres-
sion, coding for the enzyme that catalyzes the first committed 
step in BA production, or in the expression of other BA synthe-
sis genes. This suggests, therefore, that a reduction in choles-
terol production is the primary cause of reduced BAs in feces 
and plasma. Since BAs have been recently proposed to play an 
important role in the control of glucose homeostasis through 
TGR5-dependent stimulation of GLP-1 production (20), and 
since GLP-1 can increase β cell glucose competence (33), we 
tested GLP-1 plasma levels in the basal state and after re-feeding. 
No differences were found between the control and LG2KO mice, 
suggesting that GLP-1 secretion does not explain the decreased 
β cell glucose competence. In contrast, our data provide support 
for a direct role of BA action in β cells through an FXR-depen-
dent mechanism, since glucose competence of control islets was 
utilizes a distinct pathway that originates from the ER lumen 
where the active site of glucose-6-phosphatase is located and 
that depends on a membrane traffic–based mechanism.
The presence of GLUT2 in the hepatocyte membrane is never-
theless important in the fasted state, as it allows glucose equili-
brations between the cytosolic compartment and the extracellular 
milieu. Indeed, after hydrolysis of glucose-6-phosphate in the ER, 
some of the glucose returns to the cytosol, and in the absence of 
GLUT2 it cannot escape the cells and is again converted to G6P, 
leading to increased G6P intracellular concentrations in the fasted 
state (5). This leads to reduced glycogen degradation since glucose 
is an inhibitor of glycogen phosphorylase and G6P is an activator of 
glycogen synthase. Thus, suppressed glucose equilibration between 
the intracellular space and extracellular milieu in the fasted state 
leads to permanently elevated intracellular levels of glucose and 
G6P, which explains the elevated expression of ChREBP in fasted 
LG2KO livers. This can, in turn, explain the elevated expression of 
glycolytic and lipogenic genes. In contrast to what might have been 
expected from ChREBP overexpression (24), there was no steatosis 
in the liver of LG2KO mice, and VLDL secretion was only moder-
ately increased. This observation could, however, be explained by the 
lack of glucose uptake by hepatocytes, a major substrate for lipogen-
esis. Direct measurements indeed showed that de novo lipogenesis 
was no greater in LG2KO livers than in control mouse livers.
Impaired hepatic glucose and glycogen metabolism have been 
proposed to generate signals that could impact feeding control 
and energy homeostasis. Here, no modifications were observed 
in feeding, body weight and body composition, heat production, 
locomotor activity, or insulin sensitivity.
Together, these observations indicate that, in the absorptive phase, 
glucose uptake by hepatocytes is not critical for whole-body glu-
cose and energy homeostasis. This is in apparent contrast to most 
textbook descriptions of the role of liver in glucose disposal in the 
absorptive phase. However, several studies in humans and dogs have 
attempted to assess splanchnic, i.e., mostly liver, glucose disposal 
after glucose or mixed-meal ingestion. Although quite variable, 
these studies proposed that approximately 10%–25% of the ingested 
glucose is taken up by the liver (25–28). In the absence of hepatic 
glucose absorption, the amount of glucose that would normally be 
taken up by the liver appears to be redirected to skeletal muscles.
Despite the lack of an acute effect of hepatic Glut2 inactiva-
tion on glucose homeostasis, long-term observations showed the 
progressive development of glucose intolerance. This was due to 
Table 1
Primers used for quantitative RT-PCR studies
Symbol Name Forward primer Reverse primer
Acca Acetyl CoA carboxylase isoform TGGTGCAGAGGTACCGAAGTG CTGCCGCAGCAGATCCAT
Elovl6 ELOVL fatty acid elongase 6 AAAGCACCCGAACTAGGTGACA ACCAGTGCAGGAAGATCAGTTTC
F2ps Farnesyl diphosphate synthase ATGGAGATGGGCGAGTTCTTC CCGACCTTTCCCGTCACA
Fas Fatty acid synthase AGGCTGGGCTCTATGGATTA AAAAGGAGGCGTCGAACTTG
Gusb β-glucuronidase GTGATGGAGGAGCTGGTTCG AGCAGAGGAAGGCTCATTGG
Hmgcr HMG CoA reductase CTTGTGGAATGCCTTGTGATTG AGCCGAAGC AGC ACA TGAT
Hmgcs1 HMGCoA synthetase GCCGTGAACTGGGTCGAA GCATATATAGCAATGTCTCCTGCAA
Lpk Liver pyruvate kinase TGGCAAGCCTGTCGTTTGT TGGTCGAGCCTTAGTGATCA
Scd1 Stearoyl CoA desaturase CCTTCCCCTTCGACTACTCTG GCCATGCAGTCGATGAAGAA
Srebp1c Sterol regulatory element binding protein 1c GGCCGAGATGTGCGAACT TTGTTGATGAGCTGGAGCATGT
Srebp2 Sterol regulatory element binding protein 2 GCGTTCTGGAGACCATGGA ACAAAGTTGCTCTGAAAACAAATCA
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Methods
Gene targeting and generation of liver-specific Glut2-deleted mice. The GLUT2 
targeting construct was generated from genomic fragments isolated from 
a 129/Sv mouse genomic library (40). The 5′ and 3′ homology arms, 5.4 
and 3.5 kb in length, respectively, were inserted on either side of a PGK 
promoter–driven neomycin selection cassette flanked by FRT sites into 
the pBluescript KS plasmid. A 2-kb fragment of genomic DNA bearing 
exon 11, encoding the C-terminal 67 amino acids of GLUT2 including 
the last transmembrane domain and the intracellular C-terminal tail and 
flanked by loxP sites, was introduced between the 5′ homology arm and 
the neomycin-resistance cassette (Figure 1A). A PGK promoter–driven thy-
midine kinase (TK) cassette was added at the end of the 3′ homology arm. 
Exponentially growing HM-1 ES cells (41) were electroporated with the lin-
earized target construct DNA and selected on plates containing G418 and 
ganciclovir. The targeted clones were identified by PCR across both homol-
ogy arms, with confirmation by Southern blot analysis. Cell populations 
expanded from the targeted clones were injected into C57BL/6 blastocysts, 
and animals displaying germline transmission were mated with C57BL/6 
mice. The resulting offspring were bred with SA-CRE-ERT2 mice, in which 
the coding sequence of tamoxifen-dependent CRE-ERT2 recombinase was 
inserted into the 3′ untranslated region of the serum albumin (SA) gene 
(17), thus enabling tamoxifen-dependent CRE expression in hepatocytes. 
PCR analysis was used to genotype the mice. Genetic inactivation of the 
Glut2 gene was induced by 3 consecutive daily i.p. injections of Glut2lox/lox; 
SA-CRE-ERT2/SA-CRE-ERT2 mice with 1 mg tamoxifen dissolved in 100 μl 
sunflower oil (LG2KO mice). The same mice injected with oil served as 
controls. In some experiments, tamoxifen was injected into Glut2lox/lox; 
SA(WT)/SA(WT) mice as controls for the tamoxifen effect.
Mice, animal housing, and feeding. Animals were housed on a 12-hour 
light/dark cycle (0700 on, 1900 off) and were fed ad libitum a standard 
rodent chow (Diet 3436; Provimi Kliba AG). Mice were housed 4–5 per 
cage at 23°C. For the fasting and re-feeding experiments, mice were fasted 
for 24 hours, or fasted for 24 hours and re-fed for 6 hours. Ripglut1;Glut2–/– 
mice (19) backcrossed for 10 generations with C57BL6 mice were used for 
some experiments using C57BL/6 mice as controls. Fxr–/– mice have been 
previously described (42).
PET. In vivo measurement of hepatic glucose uptake was performed 
using PET. Two months after Glut2 deletion, mice were fasted for 12 or 
18 hours in order to completely deplete liver glycogen stores. They were 
anesthetized with a mixture of 1.5% isoflurane in 100% O2 (0.9 l/ml, 
2.5 bars) and a catheter was cannulated into the femoral or tail vein. There-
after, mice were given a 3 g/kg oral load of glucose 10–15 minutes prior to 
PET scanning. Sixty-minute dynamic scans were acquired with the field 
of view centered on the mouse midsection. 18FDG (~60 MBq) was injected 
as a bolus through the femoral or tail vein catheter within the first 10 sec-
onds of the PET scan, followed by 300 to 500 μl of saline chase solution. 
Imaging was performed using an avalanche photodiode microPET scanner 
(LabPET4; Gamma Medic). During the entire scanning period, mice were 
maintained under 1% isoflurane anesthesia in oxygen delivered at 0.9 liters 
per minute using a face mask and under temperature and breathing rate 
monitoring. An energy window of 250 to 650 keV and a coincidence timing 
window of 22.2 nanoseconds were used. The amount of 18FDG activity in 
the field of view (FOV), which is related to the amount of single events 
per second detected by the scanner, was used to evaluate and control the 
i.v. delivery of substrate. For image reconstruction, storage of coincidence 
events recorded in list mode files during the PET scan were binned accord-
ing to their line of response, i.e., histograms using an iterative maximum 
likelihood expectation maximum–based (MLEM-based) image recon-
struction algorithm (43) in a cylindrical volume of 46 mm in diameter and 
3.7 cm in length. Voxel size measured 0.5 × 0.5 × 1.2 mm, giving a typical 
clearly increased by prior exposure to CDCA or the FXR agonist 
GW4064, an effect that was suppressed in Fxr–/– islets. This is in 
agreement with observations that BAs increase insulin produc-
tion and secretion, and also reduce islet ER stress through long-
term transcriptional effects (21, 22). However, it is worth noting 
that the effect on glucose competence of 48-hour pre-exposure 
of primary islets to FXR agonists was much lower than that 
induced by GLP-1. Thus, the trophic effect of BAs on β cell func-
tion is of relatively low potency, which is compatible with the 
fact that glucose intolerance became obvious only several weeks 
after hepatic Glut2 inactivation. Also, a recent study (34) demon-
strated an acute stimulation of insulin secretion by BAs through 
an FXR-dependent regulation of KATP channels. This observation 
is, however, different from ours since we could not find any acute 
effect of BAs on glucose-stimulated insulin secretion, but instead 
found a marked adaptation of β cell glucose competence after 
prolonged incubation with BAs.
Our present data may appear to contradict some recent stud-
ies showing that BA sequestrants improve glucose homeostasis in 
different experimental conditions (35). For instance, treatment 
with colesevelam improves glucose homeostasis in diabetic mice, 
but this occurs without changing the total BA pool (36, 37). There 
is also evidence that improvement of glucose homeostasis upon 
sequestrant treatment is mediated by increased GLP-1 secretion 
induced by the ingested fat that is not absorbed when intestinal 
BAs are reduced (38). Thus, there are different mechanisms by 
which modulation of BA pools can impact glucose homeostasis. 
In addition, BAs form a family of structurally related but very 
diverse molecules (39) that may have widely different biological 
actions. Also, our present study provides an alternate mode of 
action of BAs on β cell glucose competence that is observed only 
in long-term studies. Thus, much more work will be required to 
fully elucidate the role of BAs on diverse aspects of the control of 
glucose homeostasis. Finally, since cholesterol is the precursor of 
other biologically active substances, such as isoprenoid, dolichol, 
or steroids, it may be that other cholesterol-derived molecules also 
have an impact on β cell function.
Collectively, our data show that hepatic glucose uptake 
depends on GLUT2 expression, but the presence of this trans-
porter is dispensable for normal glycemic control during the 
absorptive phase and for a normal rate of hepatic glucose pro-
duction in the fasted state. However, during fasting, GLUT2 is 
required for equilibration of cytosolic glucose with the external 
space to allow normal glycogen mobilization and suppression of 
glycolytic and lipogenic gene expression, processes activated by 
elevated glucose levels. In LG2KO hepatocytes, the permanent 
elevation of intracellular glucose (and G6P) leads to deregu-
lated glucose and glycogen metabolism, but this does not affect 
feeding or energy homeostasis. However, in long-term studies, 
deregulation of liver metabolism leads to decreased β cell glucose 
competence, suggesting a link between liver metabolism and β 
cell function. Because the cholesterol biosynthetic pathway was 
the only metabolic pathway found to be downregulated, and 
since this was associated with decreased BA levels, we propose 
that BAs may mediate a liver/β cell axis by maintaining the glu-
cose competence of these cells through an FXR-dependent mech-
anism. These data therefore provide evidence for an interaction 
between hepatic glucose handling as a means to sense glycemic 
levels and the long-term maintenance of an appropriate insulin 
secretory capacity of the endocrine pancreas.
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lactate were measured with a Hitachi robot (Roche) according to the manu-
facturer’s instructions. For hepatic VLDL secretion rate determination, mice 
were fasted overnight and 500 mg/kg of Tyloxapol (a lipoprotein lipase inhib-
itor; Sigma-Aldrich) was injected i.v. Blood was collected at 0, 60, 120, and 
180 minutes. Total plasma TGs were determined using a commercial kit 
(Wako Chemicals GmbH). The distribution of lipids within the plasma lipo-
protein fractions was assessed after overnight fasting by separating the plasma 
samples using fast protein liquid chromatography (FPLC) with a Superose 6 
10/30 column (Pharmacia Fine Chemicals) (52). TGs and cholesterol were 
determined in each fraction using commercial kits (Wako Chemicals GmbH).
To measure plasma GLP-1 levels, 16-hour–fasted mice were re-fed for 
30 minutes, then anesthetized with isoflurane, and blood was immediately 
collected from the portal vein into tubes containing 0.28 units/ml apro-
tinin, 12.5 mM EDTA, 0.1 μM diprotin, and kept on ice until centrifuga-
tion at 4°C. Active GLP-1 content was measured using an RIA kit (Linco 
Research, Millipore). Insulin was measured using an ultrasensitive mouse 
insulin ELISA (Mercodia). Glucagon was measured by RIA (Linco Research).
Study of glucose metabolism and insulin sensitivity. For glucose tolerance tests, 
16-hour–fasted mice were i.p. injected with glucose (1 g/kg) and blood glu-
cose levels were determined from tail-tip bleedings at the indicated times 
relative to glucose injections. In vivo glucose-stimulated insulin secretion 
was determined in separate experiments on plasma samples prepared 
30 minutes before and 30 minutes after glucose injection. Hyperinsulinemic 
euglycemic clamp studies were performed on 16-week-old mice (2-month 
tamoxifen treatment). An indwelling catheter for insulin and glucose infu-
sion was placed into the left femoral vein under isoflurane anesthesia. Mice 
were allowed to recover for 6 to 8 days until they had regained 95%–100% of 
their initial body weight. After a 5-hour fast, a 180-minute hyperinsuline-
mic euglycemic clamp was conducted in awake, freely moving mice, as pre-
viously described (48). HPLC-purified [3-3H]-glucose (NEN Life Sciences, 
PerkinElmer) was prime infused throughout the clamp (5 μCi bolus, fol-
lowed by 0.05 μCi/min [basal] and 0.1 μCi/min [clamp]) to estimate glucose 
turnover and hepatic glucose production. After an 80-minute basal period, 
a blood sample was collected from the tail tip for determination of basal 
glucose turnover. The clamp was initiated by prime infusion of human insu-
lin (2.5 mU/kg/min; Actrapid; Novo Nordisk), and 50% glucose was infused 
at variable rates and adjusted every 10 minutes to clamp plasma glucose 
levels around 5.5 mM (100 mg/dl) as measured in 2-μl blood samples. With 
this dose of insulin, hepatic glucose production is partially suppressed (53). 
After a 2-hour stabilization period, a bolus (10 μCi) of 2-deoxy-D-[1-14C]-
glucose (2-[14C]DG; NEN Life Sciences, PerkinElmer) was injected for the 
determination of insulin-stimulated glucose uptake in individual tissues. 
Blood was sampled from the tail tip at 5, 15, 25, 35, and 45 minutes after 
bolus injection. At the end of the clamp study, mice were euthanized and 
tissues were collected and frozen in liquid nitrogen for subsequent analysis. 
Glucose concentrations in plasma samples were measured using a glucose 
oxidation method (Thermo Electron), and [3H]glucose was quantified as 
previously described (54). Rates of basal and clamp glucose turnover were 
determined as the ratio of the [3-3H]glucose infusion rate to the specific 
activity of plasma glucose at the end of the basal period and during the final 
40 minutes of the clamp period, respectively. Hepatic glucose production 
was determined by subtracting the rate of glucose infusion from the rate of 
whole-body glucose uptake. For the determination of tissue 2-[14C]DG-6-
phosphate (2-DG-6-P) content, tissue samples were homogenized and 
the supernatants were passed through ion-exchange columns to separate 
2-DG-6-P from 2-DG, as previously described (55).
Pancreas perfusion and islet insulin secretion. Pancreas perfusion was per-
formed as described (56). For islet perifusion experiments, islets were iso-
lated by hand picking after collagenase digestion of the pancreas and same-
size islets were chosen for secretion experiments performed as described 
resolution of 1.2 mm at the center of the FOV. For temporal histogram-
ming the datasets were sorted into 5-second frames for 2 minutes; 30-sec-
ond frames for 3 minutes; 2-minute frames for 10 minutes; and 5-minute 
frames for 35 minutes. Subsequent to correction for the different count 
rates of each line of response and quantitative calibration of 18FDG, images 
of accumulated intracellular 18FDG-6P at steady state were quantitatively 
expressed using the standardized uptake value (SUV), i.e.: (mean region of 
interest [ROI] activity [kBq/cm3])/(injected dose [kBq]/body weight [g]). 
Images were corrected for nonuniformity of the scanner response, dead-
time count losses, and physical decay to the time of injection. No correc-
tion was applied for attenuation and partial-volume effects. Images were 
analyzed with PMOD 3.0 software (PMOD Technologies). The ROI was 
drawn manually by optical reading of well-delineated liver tissue and used 
to calculate the time-activity curve for the liver, expressed in grams per 
milliliter. The time-activity curve of the vena cava was used to detect the 
precise time of bolus injection and as a control representative of the basal 
radioactivity in blood vessels.
Histology and immunohistochemistry. For histology analysis, livers and other 
tissues were fixed in 4% paraformaldehyde for 4 hours, then left overnight 
in 40% sucrose and kept at –80°C. Twenty-micrometer cryosections were 
prepared for H&E and oil red O staining. Immunohistochemical detection 
of GLUT2 was performed as described (44) using an anti-rabbit immuno-
globulin secondary antibody from the Dako EnVision Plus system.
Immunoblotting. Western blot analysis of tissue membrane preparations 
was performed as described (44). For quantification of nuclear proteins, 
nuclei were purified from fresh liver as described (45). Protein concentra-
tions were measured using the BC Assay reagent (Interchim). ChREBP anti-
bodies were purchased from Novus Biologicals.
RNA preparations and qRT-PCR analysis. Total RNA was extracted using 
the peqGOLD TriFast method (Peqlab), and real-time RT-PCR analysis 
was performed using a 7500 Fast Real-Time PCR system (Applied Bio-
systems). Single-strand cDNA was synthesized with random hexamers 
(Applied Biosystems) and Superscript II reverse transcriptase (Invitrogen). 
RT-PCR reactions were prepared in a final volume of 10 μl containing 
2 μl of reverse-transcribed total RNA and 5 μl of Power SYBR Green PCR 
master mix (Applied Biosystems) in the presence of forward (F) and reverse 
(R) primers at 0.3 μM (primer sequences are listed in Table 1). Expression 
values were normalized to the expression level of β-glucuronidase (Gusb).
Liver triglyceride and cholesterol content and de novo lipogenesis. Total lipids 
were extracted from harvested liver by a modified Folch method (46). 
Triglycerides (TGs) and cholesterol were separated by use of solid-phase 
extraction (SPE) columns (47). Isolated TGs, cholesterol, and standards 
were then mixed with chloroform-Triton X (1%) solution, dried under N2 
gas, and dissolved into water. TG and cholesterol content were then mea-
sured by Wako Chemical kits (Wako Chemicals GmbH). De novo lipogene-
sis was measured by stable isotope incorporation with analysis by gas chro-
matography-mass spectrometry (GC-MS). Mice were labeled with an i.p. 
injection (20 μl/g body weight) of pure 2H2O (Cambridge Isotope Labora-
tories) 24 hours before sacrifice and then given 8% 2H2O as drinking water 
until the end of the experiment. All procedures were as described (48–50).
Liver glycogen content. Liver glycogen content was determined as described 
previously (51). Briefly, 100 mg of liver tissue was dissolved in 6 volumes of 
1 M NaOH for 1 hour at 55°C and neutralized with 1 N HCl. The extract 
was spun down and aliquots of the supernatant were incubated in the pres-
ence of amyloglucosidase for 2 hours at 37°C under vigorous shaking in a 
0.2-M sodium acetate buffer. The glucose was then assayed using a Trinder 
glucose oxidase method (Sigma-Aldrich).
Blood parameters and plasma hormones and lipoprotein determinations. Blood 
glucose levels were measured using an Ascensia Breeze2 glucometer (Bayer 
Healthcare). Plasma concentration of total cholesterol, HDL, LDL, TGs, and 
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Body composition, energy homeostasis. Fat and lean body masses were deter-
mined on isoflurane-anesthesized animals using an EchoMRI whole-body 
composition analyzer. Indirect calorimetry was performed 1 month after 
Glut2 deletion using an 8-chamber Oxymax system (Columbus Instru-
ments). Gas concentrations were monitored at the inlet and outlet of the 
sealed chambers. Oxygen consumption (VO2) and carbon dioxide produc-
tion (VCO2) were calculated and used to assess energy expenditure (heat 
production) and respiratory quotient (RER). Mice were allowed to accli-
mate to the cages for 2 days before 1 or 2 cycles of 24-hour measurements.
Statistics. All data are mean ± SEM and were compared by an unpaired, 
2-tailed Student’s t test unless stated otherwise. A P value less than 0.05 was 
considered significant. P values are indicated in the figure legends.
Study approval. All experimental protocols were approved by the Service 
Vétérinaire du Canton de Vaud (Switzerland).
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(57). At the end of each perifusion, islets were collected and lysed in acid 
ethanol (75% EtOH; 0.55% HCl) for assessment of insulin content. Sepa-
rate batches of islets were used to measure insulin/DNA content. For static 
incubations, isolated islets were transferred in 12-well plates and preincu-
bated or not with BAs (chenodeoxycholic acid, CDCA, 50 μM) or the FXR 
agonist GW4064 (1 μM) for 48 hours. Islets were then preincubated for 
1 hour in 1 ml KRBH supplemented with 2.8 mM glucose, then transferred 
to 1 ml KRBH supplemented with 2.8 or 20 mM glucose. After 2 hours, 
islets and media were collected for insulin measurements.
Pancreas histology and insulin endocrine hormone determination. Mice were 
killed and the pancreas were quickly dissected, weighed, frozen in liquid 
nitrogen, and homogenized in acid ethanol. For histological analysis, 
whole pancreases were fixed with 4% paraformaldehyde and embedded in 
paraffin. Five to six sections of the whole pancreas were stained for insulin 
and β cell area was measured in all sections using ImageJ software (NIH); 
β cell mass was calculated by multiplying pancreas weight by the percent-
age of the pancreas surface occupied by β cells.
Microarray analysis. Fasted and re-fed control and LG2KO mice were killed 
15 days after tamoxifen treatment and liver RNAs were extracted using 
Trifast reagent (Peqlab). For each group, 3 pools of RNA from 3 animals 
were prepared and, following quality control, were used for hybridization 
to Affymetrix Mouse Genome 430 2.0 arrays according to the supplier’s 
instructions. The data were analyzed using R statistical software (58). Fol-
lowing normalization using the RMA package (59), 2 × 2 factorial analysis 
conducted with the Limma package (60) was used to identify differentially 
expressed genes, in particular those differentially regulated between con-
trol and LG2KO mice. GSEA was performed as previously described (18). 
Microarray data are available in the NCBI’s Gene Expression Omnibus, 
(accession number GSE43581).
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